Intriguingly, PCK2 is preferentially expressed in the mesenchymal GBM, accompanied by a positive correlation with immune cell infiltration, underscores its potential involvement in shaping the immune landscape within the tumor microenvironment. The gene discussed is PCK2; the disease is glioblastoma.